Michael Safdi

Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial

William J. Sandborn, S. B. Hanauer, Seymour Katz et al. · Gastroenterology · 2001 · 905 citations · Full text

Functional Gastrointestinal Disorder, Gastroenterology, Clinical Trials +5

Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease

Paul Rutgeerts, Robert H. Diamond, Mohan Bala et al. · Gastrointestinal Endoscopy · 2006 · 546 citations

Inflammation, Anti-inflammatory, Maintenance Treatment +6

A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis

Michael Safdi, Michael DeMicco, Charles A. Sninsky et al. · Gastroenterology · 1995 · 324 citations

Distal Ulcerative Colitis, Gastroenterology, Clinical Gastroenterology +5

Delayed-Release Oral Mesalamine at 4.8 g/day (800 mg tablet) for the Treatment of Moderately Active Ulcerative Colitis: The ASCEND II Trial

Stephen B. Hanauer, William J. Sandborn, Asher Kornbluth et al. · The American Journal of Gastroenterology · 2005 · 323 citations

Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection

Miguel Regueiro, Brian G. Feagan, Bin Zou et al. · Gastroenterology · 2016 · 320 citations · Full text